id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2005-N-0021-0009,FDA,FDA-2005-N-0021,"Letter to Symrise, Inc from FDA CDER",Other,Letter(s),2020-11-02T05:00:00Z,2020,11,2020-11-02T05:00:00Z,,2020-11-02T17:43:09Z,,0,0,09000064849469b9
FDA-2005-N-0021-0008,FDA,FDA-2005-N-0021,Climbazole TEA Letter to Representatives of Symrise Inc. and Proctor and Gamble,Other,Letter(s),2020-01-14T05:00:00Z,2020,1,2020-01-14T05:00:00Z,,2020-01-14T16:13:20Z,,0,0,09000064842a002e
FDA-2005-N-0021-0007,FDA,FDA-2005-N-0021,Letter from FDA CDER to  Representatives of Symrise Inc. re:  Climbazole TEA and Proctor & Gamble,Other,Letter(s),2019-08-29T04:00:00Z,2019,8,2019-08-29T04:00:00Z,,2020-10-29T12:59:54Z,,0,0,0900006483ed9393
FDA-2005-N-0021-0006,FDA,FDA-2005-N-0021,Feedback Letter from FDA CDER to Steinberg & Associates Inc.,Other,Letter(s),2018-12-21T05:00:00Z,2018,12,2018-12-21T05:00:00Z,,2018-12-21T13:41:05Z,,0,0,09000064839bd85a
FDA-2005-N-0021-0005,FDA,FDA-2005-N-0021,"Letter from Steinberg & Associates, Inc. to FDA",Other,Letter(s),2009-02-20T05:00:00Z,2009,2,2005-12-05T05:00:00Z,2006-03-07T04:59:59Z,2020-10-29T12:27:32Z,,0,0,090000648085fbd4
FDA-2005-N-0021-0004,FDA,FDA-2005-N-0021,Procter & Gamble Company [Climbazole] Safety and Efficacy Review - Supplement,Other,SUP-Supplement,2008-07-15T04:00:00Z,2008,7,2008-07-15T04:00:00Z,,2020-10-29T12:28:41Z,,0,0,090000648063da87
FDA-2005-N-0021-0001,FDA,FDA-2005-N-0021,Over-the-Counter Drug Products; Safety and Efficacy Review; Additional Dandruff Control Ingredient,Notice,"NRD-Notice of Requesting Data, Info, & Views",2005-12-05T05:00:00Z,2005,12,2005-12-05T05:00:00Z,2006-03-07T04:59:59Z,2020-10-29T12:03:48Z,,0,0,090000648043e759